{"id":"W3131242205","doi":"10.1016/j.cllc.2021.02.010","title":"Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Non–Small-Cell Lung Cancer (MYSTIC)","year":2021,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Merck Sharp and Dohme; Bayer Fund; Ipsen Biopharmaceuticals; Merck KGaA; Prince of Songkla University; F. Hoffmann-La Roche; AbbVie; Meso Scale Diagnostics; Sanofi; Roche; EMD Serono; Novartis; MedImmune; GlaxoSmithKline; Eli Lilly and Company; Bristol-Myers Squibb; AstraZeneca; Boehringer Ingelheim; Amgen; Pfizer","keywords":"Durvalumab; Tremelimumab; Medicine; Hazard ratio; Internal medicine; Chemotherapy; Oncology; Lung cancer; Confidence interval; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002432973,0.0005693905,0.001833696,0.00009005579,0.0001241538,0.0000350798,0.0001239104,0.0001677502,0.00248439],"category_scores_gemma":[0.00009570608,0.0003277826,0.0004405687,0.0005595926,0.000334603,0.0000808812,0.00002828529,0.0002484368,0.00000249117],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009358766,"about_ca_system_score_gemma":0.00380118,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001600146,"about_ca_topic_score_gemma":0.008021668,"domain_scores_codex":[0.9963876,0.0001171668,0.001350718,0.0008664551,0.0007440321,0.0005340044],"domain_scores_gemma":[0.9967861,0.0005737529,0.0007847243,0.000887191,0.000654123,0.0003141681],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.291817,0.002752816,0.6212834,0.0008379256,0.01340398,0.0007855288,0.001312102,0.0002508716,0.0004318493,0.00000223799,0.00103125,0.06609105],"study_design_scores_gemma":[0.5459962,0.09862597,0.1900331,0.006980303,0.03157206,0.0003008816,0.002544774,0.005264488,0.05516258,0.00001038129,0.06059217,0.002917045],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.985687,0.007974422,0.0002842526,0.002264742,0.0008546327,0.002083284,0.0001761571,0.00007805157,0.0005974791],"genre_scores_gemma":[0.9739513,0.01460423,0.002808657,0.00148292,0.0002617584,0.000702229,0.00007713637,0.0001617719,0.005949968],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4312503,"threshold_uncertainty_score":0.9999174,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05276557928474587,"score_gpt":0.3996062283725302,"score_spread":0.3468406490877843,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}